Presenter Status
Fellow
Abstract Type
Research
Primary Mentor
Keith August, MD, MS
Start Date
16-5-2024 11:30 AM
End Date
16-5-2024 1:30 PM
Presentation Type
Poster Presentation
Description
BACKGROUND: Pegaspargase (SS-PEG) became unavailable to younger patients in 2022, leaving calaspargase pegol (SC-PEG) as the only available long-acting asparaginase formulation. SC-PEG has been compared to SS-PEG and found to have similar rates of adverse events and event-free survival. Our institution uses a desensitization protocol for those with asparaginase hypersensitivity reactions. Here we review our experience with desensitization since the transition to SC-PEG. OBJECTIVES: To compare the rate of hypersensitivity reactions, success of desensitization, and need for alternative asparaginase preparations between patients receiving SC-PEG and SS-PEG. METHOD: This is a retrospective, single center study of pediatric patients who received >2 doses of SC-PEG from November 2022 – December 2023. RESULTS: We report 26 patients with acute lymphoblastic leukemia and lymphoma who received >2 doses of SC-PEG. The frequency of a grade 2 or higher clinical hypersensitivity reaction was 42.3% (n=11). Silent inactivation, defined as serum asparaginase activity (SAA)
Included in
Higher Education and Teaching Commons, Medical Education Commons, Pediatrics Commons, Science and Mathematics Education Commons
An Increased Failure Rate Of Asparaginase Desensitization With Calaspargase Pegol
BACKGROUND: Pegaspargase (SS-PEG) became unavailable to younger patients in 2022, leaving calaspargase pegol (SC-PEG) as the only available long-acting asparaginase formulation. SC-PEG has been compared to SS-PEG and found to have similar rates of adverse events and event-free survival. Our institution uses a desensitization protocol for those with asparaginase hypersensitivity reactions. Here we review our experience with desensitization since the transition to SC-PEG. OBJECTIVES: To compare the rate of hypersensitivity reactions, success of desensitization, and need for alternative asparaginase preparations between patients receiving SC-PEG and SS-PEG. METHOD: This is a retrospective, single center study of pediatric patients who received >2 doses of SC-PEG from November 2022 – December 2023. RESULTS: We report 26 patients with acute lymphoblastic leukemia and lymphoma who received >2 doses of SC-PEG. The frequency of a grade 2 or higher clinical hypersensitivity reaction was 42.3% (n=11). Silent inactivation, defined as serum asparaginase activity (SAA)
